NCT03926624 2026-01-22
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Delta-Fly Pharma, Inc.
Phase 3 Terminated
Delta-Fly Pharma, Inc.
University Hospital, Toulouse
Gilead Sciences
Kronos Bio
Cornerstone Pharmaceuticals
Wake Forest University Health Sciences
Hoffmann-La Roche
University Hospital Carl Gustav Carus
University of Ulm
University of Arkansas
French Innovative Leukemia Organisation
National Cancer Institute (NCI)
St. Jude Children's Research Hospital